Best Lynozyfic (Invoseltamab) Medicine in India

Lynozyfic (Linvoseltamab) is a targeted immunotherapy used to treat adults with relapsed or refractory multiple myeloma who have received at least four prior lines of treatment, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. It is a bispecific antibody that targets B-cell maturation antigen (BCMA) on myeloma cells and CD3 on T cells, helping the immune system recognize and destroy cancer cells.

Lynozyfic (Linvoseltamab) is administered as an intravenous infusion by a qualified healthcare professional using a step-up dosing schedule. Close monitoring is required, particularly during the initial doses, because serious cytokine release syndrome (CRS) and neurological toxicity can occur. Regular blood tests and medical assessments may be required to monitor treatment response and potential complications.

Common side effects of Lynozyfic (Linvoseltamab) may include musculoskeletal pain, cytokine release syndrome, cough, diarrhea, upper respiratory tract infection, fatigue, pneumonia, nausea, and headache. It may also cause serious neurological toxicity, infections, low blood cell counts, and liver problems. Seek immediate medical attention if you develop difficulty breathing, confusion, severe dizziness, fever, or other symptoms during or after treatment.

Treatment of Relapsed or Refractory Multiple Myeloma

Lynozyfic (Linvoseltamab) is used to treat adults with relapsed or refractory multiple myeloma who have received multiple prior treatments. It targets BCMA on myeloma cells and CD3 on T cells, helping the immune system recognize and destroy abnormal cells and helping control disease progression.

Most side effects do not require medical attention and may improve as your body adjusts to the treatment. Consult your doctor if they persist, become severe, or cause concern.

Common Side Effects of Lynozyfic (Invoseltamab)

Lynozyfic (Linvoseltamab) is given as an intravenous infusion by a qualified healthcare professional according to the treatment schedule prescribed by your doctor. Treatment begins with step-up dosing to reduce the risk of serious reactions. You may receive medicines before the infusion to help prevent or manage reactions. Close monitoring is required during and after treatment, especially during the initial doses.

Lynozyfic (Linvoseltamab) is a bispecific antibody that binds to BCMA on multiple myeloma cells and CD3 on T cells. By bringing T cells into contact with myeloma cells, it helps activate the immune system to recognize and destroy the abnormal cells, helping to reduce the number of cancer cells and control disease progression.

• Store unopened Lynozyfic vials refrigerated between 2°C and 8°C.
• Keep the vial in the original carton to protect it from light.
• Do not freeze or shake the vial during storage.
• After dilution, use the infusion solution within 8 hours at room temperature or within 48 hours when refrigerated at 2°C to 8°C.

Alcohol CONSULT YOUR DOCTOR

Avoid or limit alcohol during treatment, as it may worsen dizziness, fatigue, or other treatment-related side effects. Consult your doctor for personalized advice.

Pregnancy CONSULT YOUR DOCTOR

Lynozyfic (Linvoseltamab) may harm an unborn baby. Women who can become pregnant should use effective contraception during treatment and for the period advised by their doctor.

Breastfeeding CONSULT YOUR DOCTOR

Do not breastfeed during treatment with Lynozyfic (Linvoseltamab) and for the period recommended by your doctor.

Driving CONSULT YOUR DOCTOR

Lynozyfic (Linvoseltamab) may cause dizziness, fatigue, confusion, or neurological effects that can affect alertness. Avoid driving or operating machinery if you feel affected.

Kidney CAUTION

Inform your doctor if you have kidney problems before starting treatment. Kidney function may be monitored during treatment, especially if you develop dehydration or other complications.

Liver CAUTION

Tell your doctor about any liver problems before treatment. Liver function may be monitored during treatment as advised by your healthcare team.

• Attend all scheduled Lynozyfic (Linvoseltamab) infusions and follow your doctor's treatment plan carefully.
• Take all premedications as prescribed to help reduce the risk of infusion-related reactions.
• Stay well hydrated and get adequate rest, especially if you experience fatigue, fever, or other treatment-related effects.
• Attend regular blood tests and medical check-ups to monitor blood counts, infections, and your overall response to treatment.
• Report fever, difficulty breathing, severe dizziness, confusion, or other new or worsening symptoms immediately.
• Read More About - Lynozyfic (Invoseltamab) from Pharma Five.

Pharma Five, can assist patients with importing Lynozyfic (Linvoseltamab) in small quantities for personal use. For this purpose, the applicant is required to submit an application in Form 12A along with a prescription from a Registered Medical Practitioner (RMP).

Pharma Five supports patients requiring Lynozyfic (Linvoseltamab) through professional pharmaceutical consultancy and import facilitation services, helping facilitate access to this specialized medicine. Pharma Five provides extensive pharmaceutical service coverage across India, serving patients and healthcare requirements in prominent cities such as Mumbai, Delhi, Kolkata, Bhubaneswar, Bangalore, Hyderabad, Chennai, Ahmedbad, Pune, Surat, Visakhapatnam, Jaipur, Lucknow, Nagpur, Indore, Patna, Agartala, Guwahati, Imphal, Kohima, Namchi, Noida, Ghaziabad, Ludhiana, Agra, Varanasi, Srinagar, Amritsar, Jodhpur, Chandigarh, Gurgaon, Gorakhpur, Dehradun, Jammu, Hyderabad, Thiruvananthapuram, Kochi, Coimbatore, Puducherry, Mysuru, Salem, Vellore, Tiruppur, Guntur, Goa, Kolhapur, Mumbai, Nashik, and various other regions in India.